{"preliminary_commentary":{"by_channel":{"podcast":20,"youtube":19,"x_thread":15},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT03409614\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's free public preview; the full report is still bought."},"commentary_summary":null,"drugs_tested":[["cemiplimab"]],"indication":"first-line advanced or metastatic non-small cell lung cancer","name":"EMPOWER-Lung 3","nct_id":"NCT03409614","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=empower-lung-3-nct03409614. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1950,"size":"deep","size_rule":"Deep: 301+ verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"Part 1: Chemotherapy","label":"Chemo","type":"OTHER"},{"description":"Part 1: REGN2810+chemo","label":"REGN2810+Chemo Part 1","type":"EXPERIMENTAL"},{"description":"Part 1: REGN2810+abbrev chemo+ipi","label":"REGN2810+AbbrevChemo+ipi","type":"EXPERIMENTAL"},{"description":"Part 2: Placebo plus chemo","label":"Placebo+Chemo","type":"EXPERIMENTAL"},{"description":"Part 2: REGN2810+chemo","label":"REGN2810+Chemo Part 2","type":"EXPERIMENTAL"}],"collaborators":["Sanofi"],"completion_date":{"date":"2025-02-27","type":"ACTUAL"},"conditions":["Non-small Cell Lung Cancer"],"enrollment":{"count":789,"type":"ACTUAL"},"has_results":true,"interventions":[{"name":"REGN2810","otherNames":["cemiplimab"],"type":"DRUG"},{"name":"REGN2810/chemo/ipi","otherNames":["cemiplimab"],"type":"DRUG"},{"name":"Chemotherapy","otherNames":[],"type":"OTHER"},{"name":"Placebo","otherNames":[],"type":"DRUG"}],"last_update":"2026-05-18","lead_sponsor":"Regeneron Pharmaceuticals","official_title":"A Two-Part Randomized, Phase 3 Study of Combinations of Cemiplimab (Anti-PD-1 Antibody) and Platinum-based Doublet Chemotherapy in First-line Treatment of Patients With Advanced or Metastatic Non-Small Cell Lung Cancer","overall_status":"COMPLETED","phases":["PHASE3"],"primary_completion_date":{"date":"2025-02-27","type":"ACTUAL"},"primary_outcomes":[{"measure":"Part 1: Overall Survival (OS)","timeFrame":"Up to a maximum of 82.2 months"},{"measure":"Part 2: OS","timeFrame":"Up to a maximum of 68.4 months"}],"references":[{"citation":"Baramidze A, Makharadze T, Gogishvili M, Melkadze T, Giorgadze D, Penkov K, Laktionov K, Nemsadze G, Nechaeva M, Rozhkova I, Kalinka E, Ag McIntyre D, Perez J, Kaul M, Quek RGW, Seebach F, Rietschel P, Pouliot JF. Cemiplimab plus chemotherapy versus chemotherapy alone in non-small cell lung cancer with PD-L1 >/= 1 %: A subgroup analysis from the EMPOWER-Lung 3 part 2 trial. Lung Cancer. 2024 Jul;193:107821. doi: 10.1016/j.lungcan.2024.107821. Epub 2024 May 13.","pmid":"38820979","type":"DERIVED"},{"citation":"Zhao B, Qi H, Wu J, Ma W. Cemiplimab Plus Chemotherapy Could Be a First-Line Option for Advanced and Metastatic NSCLC: Results From the Phase 3 EMPOWER-Lung 3 Part 2 Trial. J Thorac Oncol. 2023 Jul;18(7):e72-e73. doi: 10.1016/j.jtho.2023.04.001. No abstract available.","pmid":"37348996","type":"DERIVED"},{"citation":"Makharadze T, Gogishvili M, Melkadze T, Baramidze A, Giorgadze D, Penkov K, Laktionov K, Nemsadze G, Nechaeva M, Rozhkova I, Kalinka E, Li S, Li Y, Kaul M, Quek RGW, Pouliot JF, Seebach F, Lowy I, Gullo G, Rietschel P. Cemiplimab Plus Chemotherapy Versus Chemotherapy Alone in Advanced NSCLC: 2-Year Follow-Up From the Phase 3 EMPOWER-Lung 3 Part 2 Trial. J Thorac Oncol. 2023 Jun;18(6):755-768. doi: 10.1016/j.jtho.2023.03.008. Epub 2023 Mar 29.","pmid":"37001859","type":"DERIVED"},{"citation":"Gogishvili M, Melkadze T, Makharadze T, Giorgadze D, Dvorkin M, Penkov K, Laktionov K, Nemsadze G, Nechaeva M, Rozhkova I, Kalinka E, Gessner C, Moreno-Jaime B, Passalacqua R, Li S, McGuire K, Kaul M, Paccaly A, Quek RGW, Gao B, Seebach F, Weinreich DM, Yancopoulos GD, Lowy I, Gullo G, Rietschel P. Cemiplimab plus chemotherapy versus chemotherapy alone in non-small cell lung cancer: a randomized, controlled, double-blind phase 3 trial. Nat Med. 2022 Nov;28(11):2374-2380. doi: 10.1038/s41591-022-01977-y. Epub 2022 Aug 25.","pmid":"36008722","type":"DERIVED"}],"start_date":{"date":"2018-03-06","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Combinations of Cemiplimab (Anti-PD-1 Antibody) and Platinum-based Doublet Chemotherapy in Patients With Lung Cancer","url":"https://clinicaltrials.gov/study/NCT03409614"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.1","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/empower-lung-3-nct03409614"}